SUMO: In Silico Sequence Assessment Using Multiple Optimization Parameters
Author:
Evers AndreasORCID,
Malhotra Shipra,
Bolick Wolf-Guido,
Najafian Ahmad,
Borisovska Maria,
Warszawski Shira,
Fomekong Nanfack Yves,
Kuhn Daniel,
Rippmann Friedrich,
Crespo Alejandro,
Sood Vanita
Reference53 articles.
1. Rabia LA, Desai AA, Jhajj HS, Tessier PM (2018) Understanding and overcoming trade-offs between antibody affinity, specificity, stability and solubility. Biochem Eng J 137:365–374. https://doi.org/10.1016/j.bej.2018.06.003
2. Bailly M, Mieczkowski C, Juan V et al (2020) Predicting antibody developability profiles through early stage discovery screening. mAbs 12:1743053. https://doi.org/10.1080/19420862.2020.1743053
3. Jain T, Sun T, Durand S et al (2017) Biophysical properties of the clinical-stage antibody landscape. Proc Natl Acad Sci U S A 114:944–949. https://doi.org/10.1073/pnas.1616408114
4. Jarasch A, Koll H, Regula JT et al (2015) Developability assessment during the selection of novel therapeutic antibodies. J Pharm Sci 104:1885–1898. https://doi.org/10.1002/jps.24430
5. Kingsbury JS, Saini A, Auclair SM et al (2020) A single molecular descriptor to predict solution behavior of therapeutic antibodies. Sci Adv 6:eabb0372. https://doi.org/10.1126/sciadv.abb0372
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献